Valtech Cardio Presents Data on Tricuspid, Mitral Devices at PCR London Valves 2016

September 19, 2016 — Valtech Cardio Ltd. announced that it will present the first-in-man data for its Cardioband Tricuspid (TR) system at PCR London Valves 2016, Sept. 18-20. In addition, updated two-year follow-up results of the multi-center Cardioband Mitral study will be presented at the meeting.

“I am pleased to share my first experience with Cardioband Tricuspid, which shows that it is feasible to perform a successful trans-venous surgical like annuloplasty procedure for the treatment of TR.” said Francesco Maisano, M.D, chairman and professor of cardiovascular surgery at The University Hospital of Zurich who successfully performed the first implantation of Cardioband Tricuspid. “The device has the potential to reproduce surgical standards, although our experience is still limited at the moment.”

A Valtech symposium titled, “Cardioband: Clinical Reality for Mitral and Tricuspid Valve Repair,” will be led by Eberhard Grube, M.D., Ph.D., (University of Bonn, Germany) and Karl-Heinz Kuck, M.D. (Asklepios Klinic St. Georg, Hamburg, Germany) Tuesday, Sept. 20. Panelists will discuss how they are successfully using Cardioband to apply the surgical gold standard in a transfemoral approach.

An accepted talk, “Direct annuloplasty - Cardioband in tricuspid regurgitation,” was presented by Prof. K.H. Kuck (Asklepios Klinic St. Georg, Hamburg, Germany) as part of the “innovation in percutaneous tricuspid valve intervention” session Sunday, Sept. 18.

An accepted abstract, "One Year Follow-up Results of Mitral Valve Transcatheter Annuloplasty System for Mitral Reconstruction Multicentre Trial,” will be presented by Prof. R. S. von Bardeleben (University of medicine Mainz Germany) as part of the "Mitral and Tricuspid Valve Interventions" session held Monday, Sept. 19.

An additional accepted abstract, "Cardioband implantation to treat recurrent mitral regurgitation after MitraClip therapy,” will be presented by Dr. M. Taramasso (University Hospital of Zurich) as part of the "Percutaneous mitral therapies" session Tuesday, Sept. 20.

For more information: www.valtechcardio.com